Clinical Trial Search

Primary: Change From Baseline in Maintenance of Wakefulness Test (MWT) Score at Day 21 of Stable Dosing Phase — 6.30; 5.81; 1.29; 1.10 minutes — p=0.418

Primary: Change in Psychomotor Vigilance Task (PVT) Median Reaction Time — -9.86; -4.46 msec — p=0.77

Primary: Sleep and Fatigue — 15.6; 9.0; 10.9; 6.6 units on a scale

Primary: Maintenance of Wakefulness Test (MWT) — 2.3; -1.3 Minutes — p=0.0003

Primary: Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With…

Primary: Multiple Sleep Latency Test (MSLT) — 3.1; 0.4 Minutes — p=<0.0001

Primary: Maintenance of Wakefulness Test (MWT) — 2.2; 1.7; -1.7 Minutes — p=0.0001

Primary: Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) — 20.46; 19.08 centimeter (cm) — p=0.0022

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Early Discontinuation — 1; 2; 0; 0 Participants

Primary: Change in Average Total Sleep Time — 1.83; -0.33 hours/sleep opportunity — p=<0.05

Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose

Primary: Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last…

Primary: Subjective Sleepiness — 11.8; 10.2; 9.9 units on a scale

Primary: Change in the Maintenance of Wakefulness Test (MWT) — -0.96; -12.11 minutes

Primary: Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) — 19.92; 18.83 centimeter (cm) — p=0.0062

Primary: EEG Slow Wave Activity During Sleep — 0.00002653; 0.00002257 uV^2/Hz

Primary: Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 — 2.12; 4.74; 9.77; 12.27 minutes

Primary: Change From Baseline in Maintenance of Wakefullness Test (MWT) Score at 12 Weeks — 2.6; 1.3; -1.9; 1.9 Minutes — p=0.0024

Primary: Safety Adverse Events — 0; 0; 0; 0 participants

Primary: Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 — 4.74; 9.08; 10.96; 12.99 minutes

Primary: Physical Activity, Steps Walked — 5892; 6071; 6284; 6684 steps walked

Primary: Non-REM Slow Wave Sleep — 47.3; 34.3; 57.3; 41.4 minutes

Primary: Safety and Tolerability in This Patient Population (Narcolepsy, OSAHS, SWSD) Over Time (up to 2 Years) — 667 Participants

Primary: Salivary Cortisol Level

Primary: Daytime Total Sleep Time in Minutes Per Day Collected From the Consensus Sleep Diary — 362.7; 365.3 Minutes per day — p=0.884

Primary: Psychomotor Vigilance Task (PVT) Reaction Time — 279.1; 311.6; 333.8 Msec — p=0.47

Primary: Measurement of Sleepiness Using the Epworth Sleepiness Scale (ESS) at Baseline and Post Dose. — -4.34; -4.64; -3.46; -4.73 units on a scale — p=0.668

Primary: Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at…

Primary: Safety and Tolerability as Measured by Number of Participants With Adverse Events — 323 Participants

Primary: Mean Sleep Latency Score on the Maintenance of Wakefulness Test (MWT) for Participants Taking MK-7288 Versus Placebo — 18.66; 18.62; 20.71; 10.50 Minutes